MHRA Drug Safety Update: November 2023

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 17 Issue 4 November 2023) has been published and includes articles on:

  • Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products
  • Nirmatrelvir, ritonavir (Paxlovid▼): be alert to the risk of drug interactions with ritonavir
  • E-cigarette use or vaping: reminder to remain vigilant for suspected adverse reactions and safety concerns and report them to the Yellow Card scheme
  • Letters and medicine recalls sent to healthcare professionals in September 2023.

To see the latest MHRA Drug Safety Updates in full, visit the website.